Rybelsus vs Ozempic: What the Research Shows
Rybelsus and Ozempic side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Rybelsus if…
- you prefer a daily tablet to a weekly injection: Rybelsus starts at 3 mg orally once daily (a starting dose not effective for glycemic control)[10]
- you want an oral semaglutide: Rybelsus tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes[10]
Consider Ozempic if…
Spec comparison
Showing all 11 fields. Highlighted rows differ.
| Field | Rybelsus | Ozempic |
|---|---|---|
| Class | Brand of Semaglutide (GLP-1 agonist) | Brand of Semaglutide (GLP-1 agonist) |
| Also called | Brand name of Semaglutide | Brand name of Semaglutide |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | FDA approved (Ozempic, Wegovy, Rybelsus) | FDA approved (Ozempic, Wegovy, Rybelsus) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | approximately 1 weeksubcutaneous · FDA label (Ozempic) | approximately 1 weeksubcutaneous · FDA label (Ozempic) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 |
| Human studies we summarised | 23 human (19 randomized or controlled) of 27 summarised | 23 human (19 randomized or controlled) of 27 summarised |
| Typical study doses |
|
|
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Same molecule, two routes
Both brands are semaglutide. The current oral label covers Rybelsus and Ozempic tablets together.[10]
The label states the tablets are not substitutable on a mg-to-mg basis.[10]
In an obesity trial of oral semaglutide, mean body weight change at week 64 was -13.6% against -2.2% with placebo.[8]
The Ozempic injection label includes reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.[5]
How you take each
The tablet label says to take it once daily on an empty stomach in the morning with up to 4 ounces of water, and not with other liquids.[10]
After a tablet, the label says to wait at least 30 minutes before eating, drinking or taking other oral medications.[10]
The injection label says it is given once weekly, at any time of day, with or without meals.[5]
The injection label's boxed warning states that in rodents semaglutide causes thyroid C-cell tumors at clinically relevant exposures.[5]
Common questions
Is Rybelsus as effective as Ozempic?
The tablet label says Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis, so their doses are not equivalent.[10]
Is Rybelsus the pill version of Ozempic?
The current tablet label covers Rybelsus and Ozempic tablets together: once daily, on an empty stomach in the morning with water.[10]
Does Rybelsus or Ozempic cause more weight loss?
In a separate obesity trial of oral semaglutide, mean body weight change at week 64 was -13.6% against -2.2% with placebo.[8]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 9PubMed search: (Ozempic[tiab]) AND (Rybelsus[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10RYBELSUS and OZEMPIC tablets prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.